Fate Therapeutics Inc FATE:NASDAQ

Last Price$18.20NASDAQ Closing Price as of 4:00PM ET 9/20/19
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.34(1.90%)
Bid (Size)$17.00 (5)
Ask (Size)$18.87 (5)
Day Low / High$17.76 - 18.52
Volume1.6 M
 

View Biotechnology IndustryPeer Comparison as of 09/20/2019

 

Fate Therapeutics Inc ( NASDAQ )

Price: $18.20
Change: +0.34 (1.90%)
Volume: 1.6 M
4:00PM ET 9/20/2019
 
 

Radius Health Inc ( NASDAQ )

Price: $28.47
Change: -0.39 (1.35%)
Volume: 1.7 M
4:00PM ET 9/20/2019
 
 

Momenta Pharmaceuticals Inc ( NASDAQ )

Price: $13.38
Change: +0.06 (0.45%)
Volume: 1.3 M
4:00PM ET 9/20/2019
 
 

Enanta Pharmaceuticals Inc ( NASDAQ )

Price: $71.74
Change: +0.73 (1.03%)
Volume: 324.0 K
4:00PM ET 9/20/2019
 
 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $22.66
Change: +0.16 (0.71%)
Volume: 2.0 M
4:00PM ET 9/20/2019
 

Read more news Recent News

Significant Insider buy of Fate Therapeutics (FATE) Shares Reverses Selling Trend of Last Quarter
10:17PM ET 9/18/2019 MT Newswires

One insider -- Redmile Group Llc, 10% Owner and Director -- today, acquired 857,143 shares of Fate Therapeutics having a market value of approximately...

Fate Therapeutics Closes Stock Offering; Underwriters Boost Gross Proceeds Over $173 Million
4:12PM ET 9/18/2019 MT Newswires

Fate Therapeutics (FATE) slipped 1% in extended trade after the biopharmaceuticals company late Wednesday said underwriters participating in its recent...

Significant Insider buy of Fate Therapeutics (FATE) Shares Reverses Selling Trend of Last Quarter
9:53AM ET 9/18/2019 MT Newswires

One Fate Therapeutics insider -- Redmile Group Llc, 10% Owner and Director -- today, acquired 857,143 shares having a market value of approximately...

Insider Trends: Insider Buying Prolonged with Purchase of Fate Therapeutics Stock
4:24PM ET 9/17/2019 MT Newswires

Redmile Group Llc, 10% Owner and Director, reported a purchase of 857,143 shares of Fate Therapeutics (FATE) on Sep 16, 2019, for $15,000,003. Redmile...

Company Profile

Business DescriptionFate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. View company web site for more details
Address3535 General Atomics Court
San Diego, California 92121
Phone+1.858.875.1800
Number of Employees104
Recent SEC Filing09/17/2019SC 13D/A
President, Chief Executive Officer & DirectorJ. Scott Wolchko
Chief Scientific OfficerDaniel D. Shoemaker
Vice President-Clinical DevelopmentYu Waye Chu
Senior Vice President-Corporate DevelopmentJim Beitel

Company Highlights

Price Open$17.85
Previous Close$17.86
52 Week Range$11.00 - 22.82
Market Capitalization$1.2 B
Shares Outstanding65.4 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/07/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.22
Beta vs. S&P 500N/A
Revenue$4.7 M
Net Profit Margin-934.70%
Return on Equity-50.05%

Analyst Ratings as of 08/08/2019

Buy
12
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset